

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Rycarfa 20 mg tablets for dogs  
Carprofen

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains:

**Active substance:**

Carprofen 20.00 mg

**3. PHARMACEUTICAL FORM**

Tablet.

**4. PACKAGE SIZE**

20 tablets  
50 tablets  
100 tablets  
500 tablets

**5. TARGET SPECIES**

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Oral use.

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP:

Return any halved tablet to the opened blister and use within 24 hours.

**11. SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from light and moisture.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

KRKA, d.d., Novo mesto  
Šmarješka cesta 6  
8501 Novo mesto  
Slovenia

**16. MARKETING AUTHORISATION NUMBER(S)**

Vm 01656/4069

**17. MANUFACTURER'S BATCH NUMBER**

Lot:

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**BLISTERS**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Rycarfa 20 mg tablets for dogs  
Carprofen

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

KRKA

**3. EXPIRY DATE**

EXP:

**4. BATCH NUMBER**

Lot:

**5. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

## PACKAGE LEAFLET:

### Rycarfa 20 mg tablets for dogs

#### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

KRKA, d.d., Novo mesto  
Šmarješka cesta 6  
8501 Novo mesto  
Slovenia

Manufacturer responsible for batch release:

KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia  
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia  
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany

#### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Rycarfa 20 mg tablets for dogs  
Carprofen

#### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each tablet contains:

Active substance:

Carprofen 20.00 mg

Excipients:

Ferric oxide red (E172) 0.61 mg

Ferric oxide black (E172) 0.38 mg

Round, dark brown, marbled tablets with visible darker spots, one-side scored and bevel-edged.

The tablet can be divided into equal parts.

#### 4. INDICATION(S)

Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain.

#### 5. CONTRAINDICATIONS

Do not use in cats.

Do not use in pregnant or lactating bitches.

Do not use in dogs less than 4 months of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.

## **6. ADVERSE REACTIONS**

Typical undesirable effects associated with non-steroidal anti-inflammatory drugs (NSAIDs) such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, even those not already listed in this package leaflet, use of the product should be stopped and the veterinary surgeon should be informed. As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

## **7. TARGET SPECIES**

Dogs.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

For oral administration.

2 to 4 mg carprofen per kg bodyweight per day.

An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses may, subject to clinical response, be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose.

Duration of treatment will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.

To extend analgesic and anti-inflammatory cover post-operatively, parenteral preoperative treatment may be followed with Carprofen tablets at 4 mg/kg/day for up to 5 days.

To ensure a correct dosage, body weight should be determined as accurately as possible to avoid underdosing.

## **9. ADVICE ON CORRECT ADMINISTRATION**

## **10. WITHDRAWAL PERIOD(S)**

Not applicable.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Store in the original package in order to protect from light and moisture.

Return any halved tablet to the opened blister and use within 24 hours.

Do not use this veterinary medicinal product after the expiry date which is stated on the packaging after {EXP}. The expiry date refers to the last day of that month.

## **12. SPECIAL WARNING(S)**

### Special precautions for use in animals:

Use in aged dogs, may involve additional risk.

If such a use cannot be avoided, dogs may require careful symptomatic management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

See also "Interactions".

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product.

### Pregnancy and lactation:

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the

veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.

Interaction with other medicinal products and other forms of interaction

Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of administration of the product. Carprofen is highly bound to plasma proteins and may compete with other highly bound drugs, which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided.

Overdose (symptoms, emergency procedures, antidotes)

Although studies investigating the safety of carprofen at overdose have been performed, no signs of toxicity appeared when dogs were treated with carprofen at levels up to 6 mg/kg twice daily for 7 days (3 times the recommended dose rate of 4mg/kg) and 6mg/kg once daily for a further 7 days. (1.5 times the recommended dose rate of 4 mg/kg).

There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

**15. OTHER INFORMATION**

20 mg tablets are available in boxes of 20, 50, 100 and 500 tablets in blisters of 10 tablets.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Approved 06 February 2020

